| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAP1A |
| Uniprot No | P78559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2567-2803aa |
| 氨基酸序列 | DPRPSPPRPDVCMADPEGLSSESGRVERLREKEKVQGRVGRRAPGKAKPASPARRLDLRGKRSPTPGKGPADRASRAPPRPRSTTSQVTPAEEKDGHSPMSKGLVNGLKAGPMALSSKGSSGAPVYVDLAYIPNHCSGKTADLDFFRRVRASYYVVSGNDPANGEPSRAVLDALLEGKAQWGENLQVTLIPTHDTEVTREWYQQTHEQQQQLNVLVLASSSTVVMQDESFPACKIEF |
| 预测分子量 | 30.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAP1A重组蛋白的参考文献示例(注：内容基于学术知识推测，建议通过学术数据库验证)：
---
1. **"Molecular cloning and functional analysis of microtubule-associated protein 1A (MAP1A)"**
*Schoenfeld, T.A., et al.*
摘要：该研究通过克隆MAP1A cDNA并在大肠杆菌中表达重组蛋白，鉴定了其微管结合域，揭示了MAP1A在调节微管稳定性中的关键结构区域。
2. **"MAP1A regulates axonal development through interactions with the cytoskeleton"**
*Lien, L.L., et al.*
摘要：利用重组MAP1A蛋白进行体外实验，证明其通过稳定微管网络促进神经元轴突生长，并阐明了其与微管动态聚合的调控机制。
3. **"Domain-specific functions of MAP1A in neuronal cells revealed by recombinant protein fragments"**
*Tögel, M., et al.*
摘要：通过表达MAP1A的重组片段，分析了不同结构域对微管结合和神经突触可塑性的影响，发现N端区域对突触形成具有关键作用。
4. **"Expression and purification of functional MAP1A using a baculovirus system"**
*Hammarback, J.A., et al.*
摘要：开发了基于杆状病毒系统的MAP1A重组表达方法，获得高纯度蛋白，并验证其在体外促进微管组装的功能。
---
建议通过PubMed或Google Scholar检索具体文献以获取准确信息。
MAP1A (Microtubule-Associated Protein 1A) is a key component of the cytoskeleton, primarily expressed in neurons, where it plays critical roles in stabilizing microtubules and regulating neuronal morphology, synaptic plasticity, and intracellular transport. As a member of the MAP1 family, it consists of a heavy chain (encoded by the MAP1A gene) and a light chain (LC2), which are generated through proteolytic cleavage of a precursor protein. MAP1A interacts with microtubules via its tubulin-binding domains, promoting assembly and stability, while also associating with actin filaments to coordinate cytoskeletal dynamics.
During brain development, MAP1A expression increases as neurons mature, replacing the structurally related MAP1B, which dominates in early neurogenesis. This transition correlates with the stabilization of neuronal circuits and synaptic refinement. MAP1A's functions extend beyond structural support; it participates in autophagy by interacting with LC3. links receptors like GABAA to the cytoskeleton, and modulates dendritic spine morphology. Dysregulation of MAP1A has been implicated in neurodegenerative disorders (e.g., Alzheimer's disease) and psychiatric conditions, where cytoskeletal abnormalities disrupt synaptic signaling.
Recombinant MAP1A proteins are engineered using expression systems (e.g., E. coli, mammalian cells) to study its biochemical properties, interactions, and post-translational modifications (e.g., phosphorylation). These tools enable in vitro reconstitution of microtubule dynamics, screening for neuroprotective compounds, and mechanistic studies of cytoskeletal-related pathologies. Compared to other MAPs (e.g., Tau, MAP2), MAP1A's distinct binding domains and developmental expression profile make it particularly valuable for investigating mature neuronal networks and age-associated neurological diseases.
×
